Q4 FY26 Results (April 2026)
Expected: 2026-04-01/2026-04-30HIGH confidence
Record full-year margins to validate sustainability of 35%+ operating profit
“Three consecutive quarters of margin expansion with Q3 at 35.66% (highest in 12 quarters)”
Glaxosmithkline Pharmaceuticals Ltd: Stock Analysis & Fundamentals
Updated this weekGlaxosmithkline Pharmaceuticals Ltd (Pharma - MNC bulk Drugs) — fundamental analysis, earnings data, and key metrics. PE: 38.1. ROE: 46.9%. This stock is not currently in the Nifty 500 momentum outperformers list.
What's Happening
📊Debt increased 260% YoY — leverage rising
Re-Rating Catalysts
1. Q4 FY26 Results (April 2026)
2026-04-01/2026-04-30HIGH
2. Strategic Portfolio Review Completion (June 2026)
2026-06-01/2026-06-30MEDIUM
3. New Product Launch Pipeline (July 2026)
2026-07-01/2026-07-30MEDIUM
Value Trap Risks
1. Regulatory Risk
HIGH2. Portfolio Limitations
MEDIUM3. Parent Company Strategy
MEDIUMKey Numbers
Current Price
₹2,260
Dividend Yield
1.86%
Market Cap
38.3K Cr
Valuation
N/AIs Glaxosmithkline Pharmaceuticals Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Mar 28, 2026
Margin-led turnaround with record 35.66% operating margins and first ₹1,000+ crore revenue quarter signaling sustainable profitability ahead of industry recovery.
Verdict
TURNAROUND_IN_PROGRESS
What Could Re-Rate Glaxosmithkline Pharmaceuticals Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Mar 28, 2026
Strategic Portfolio Review Completion (June 2026)
Expected: 2026-06-01/2026-06-30MEDIUM confidence
Potential divestment of non-core assets to unlock ₹500-700 crore value
“Company's strong cash position of ₹2,426 crore and focus on portfolio optimization”
New Product Launch Pipeline (July 2026)
Expected: 2026-07-01/2026-07-30MEDIUM confidence+₹150 Cr revenue
3-4 specialty drugs expected to drive 15%+ volume growth in H2 FY27
Impact: +₹150 Cr revenue
“Management commentary on strategic focus on innovation and specialty products”
Share Buyback Announcement (Q1 FY27)
Expected: 2026-07-01/2026-09-30MEDIUM confidence
Management likely to deploy ₹500+ crore from strong cash position
“Cash balance of ₹2,426 crore with limited capital expenditure requirements”
What Are the Value Trap Risks for Glaxosmithkline Pharmaceuticals Ltd?
Risks that could prevent re-rating or deepen the value trap
Regulatory Risk
HIGHGovernment announcement of price caps on essential medicines
Impact: -800 bps margin impact
Management view: Management stated implementation of new Labour Codes had no material impact, suggesting preparedness for regulatory changes
Monitor: Quarterly price realization data for essential drug portfolio
Portfolio Limitations
MEDIUMFailure to launch 3+ specialty drugs by Q3 FY27
Impact: -500 bps margin impact
Management view: Management highlighted strategic focus on innovation and portfolio diversification
Monitor: New product launch cadence and market share in specialty segments
Parent Company Strategy
MEDIUMAnnouncement of stake reduction by parent company
Management view: Parent company continues to support Indian operations as key growth market
Monitor: Changes in intercompany transactions and R&D collaboration
What Is Glaxosmithkline Pharmaceuticals Ltd's Management Guidance?
Forward-looking targets from management for FY27
Revenue Growth Target
8%
Implied PAT Growth
25%
OPM Guidance
35%
Capex Plan
₹50 Cr
Management Tone: CAUTIOUS
Key Milestones
• Completion of strategic portfolio review by June 2026
• Launch of 3-4 specialty drugs by September 2026
• Potential share buyback announcement in Q1 FY27
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Mar 28, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Glaxosmithkline Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Glaxosmithkline Pharmaceuticals Ltd's latest quarterly results?
Glaxosmithkline Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +28.7%
- Revenue Growth YoY: +9.7%
- Operating Margin: 36.0%
What is Glaxosmithkline Pharmaceuticals Ltd's current PE ratio?
Glaxosmithkline Pharmaceuticals Ltd's current PE ratio is 38.1x.
- Current PE: 38.1x
- Market Cap: 38.3K Cr
- Dividend Yield: 1.86%
What is Glaxosmithkline Pharmaceuticals Ltd's price-to-book ratio?
Glaxosmithkline Pharmaceuticals Ltd's price-to-book ratio is 22.4x.
- Price-to-Book (P/B): 22.4x
- Book Value per Share: ₹101
- Current Price: ₹2260
Is Glaxosmithkline Pharmaceuticals Ltd a fundamentally strong company?
Glaxosmithkline Pharmaceuticals Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 63.0%
Is Glaxosmithkline Pharmaceuticals Ltd debt free?
Glaxosmithkline Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹10 Cr
What is Glaxosmithkline Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Glaxosmithkline Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 36.0%
- FY2024: ROCE 51.0%
- FY2025: ROCE 63.0%
Is Glaxosmithkline Pharmaceuticals Ltd's cash flow positive?
Glaxosmithkline Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹1,000 Cr
- Free Cash Flow (FCF): ₹1,000 Cr
- CFO/PAT Ratio: 139% (strong cash conversion)
What is Glaxosmithkline Pharmaceuticals Ltd's dividend yield?
Glaxosmithkline Pharmaceuticals Ltd's current dividend yield is 1.86%.
- Dividend Yield: 1.86%
- Current Price: ₹2260
Who holds Glaxosmithkline Pharmaceuticals Ltd shares — promoters, FII, DII?
Glaxosmithkline Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
- Promoters: 75.0%
- FII (Foreign): 4.6%
- DII (Domestic): 7.7%
- Public: 12.7%
Is promoter holding increasing or decreasing in Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 75.0% (Dec 2025)
- Previous Quarter: 75.0% (Sep 2025)
- Change: 0.00% (stable)
Is Glaxosmithkline Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Glaxosmithkline Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has 4 key growth catalysts identified from recent earnings analysis
- Q4 FY26 Results (April 2026)
- Strategic Portfolio Review Completion (June 2026)
- New Product Launch Pipeline (July 2026)
- Share Buyback Announcement (Q1 FY27)
What are the key risks in Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has 3 key risks worth monitoring
- Regulatory Risk
- Portfolio Limitations
- Parent Company Strategy
What is Glaxosmithkline Pharmaceuticals Ltd's management guidance for growth?
Glaxosmithkline Pharmaceuticals Ltd's management has provided the following forward guidance for FY27
- Revenue growth target: 8%
- Implied PAT growth: 25%
- OPM guidance: 35%
- Capex plan: ₹50 Cr
- Management tone: cautious
- Milestone: Completion of strategic portfolio review by June 2026
- Milestone: Launch of 3-4 specialty drugs by September 2026
Is Glaxosmithkline Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Glaxosmithkline Pharmaceuticals Ltd may be worth studying
- Cash flow is positive — CFO ₹1,000 Cr
What is the investment thesis for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Q4 FY26 Results (April 2026)
Risk Factors (Bear Case)
- Key risk: Regulatory Risk
What is the future outlook for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's forward outlook based on current data signals
- Key Catalyst: Q4 FY26 Results (April 2026)
- Key Risk: Regulatory Risk
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.